Dallas, TX (April 14, 2015) – Amniotic Therapies (www.amniotictherapies.com), a company specialized in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market, announced that the introduction of new products at the 2015 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting has promoted growth for the business.
Amniotic Therapies’ new products included two additions to its AlphaGEMS flowable amniotic tissue line, AlphaGEMS Micro and AlphaGEMS Nano; and a new line of dehydrated amniotic tissue patches and discs for the ocular market, AlphaVISION.
The AAOS meeting is the largest annual orthopaedic meeting in the United States and was attended by over 31,000 orthopaedic surgeons and healthcare professionals.
Amniotic Therapies CEO, Neil Riordan, PhD said, “The AAOS meeting gave us the opportunity to showcase our products to physicians, health care professionals and current and potential distribution partners. Our products contain high levels of bioactive substances and growth factors that are important for healing and tissue regeneration. These factors also modulate inflammation and help reduce the formation of scar tissue. We are excited by the number of partnerships formed during and because of the meeting.”
Amniotic Therapies and its partner company, Biologic Therapies, conducted live presentations on amniotic tissue and regenerative medicine during the meeting. According to Scott Reynolds, VP of Marketing, “The presentations were well attended and were a great way to get members of our target market to witness the benefits of our products first hand.”